OTCM
IVRN
Market cap2kUSD
Oct 07, Last price
0.00USD
1D
-25.00%
Jan 2017
-99.98%
IPO
-99.99%
Name
H-Cyte Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
H-CYTE, Inc. is a biopharmaceutical firm based in the United States, dedicated to developing and supplying a range of treatments for individuals afflicted with persistent respiratory and pulmonary diseases. The company's core strategy involves pioneering and deploying autologous cellular therapy solutions specifically for chronic lung conditions. Additionally, H-CYTE maintains a product supply agreement with Rion, LLC, focused on advancing and distributing a biologic compound designed to combat chronic obstructive pulmonary disease (COPD). Its corporate headquarters are situated in Tampa, Florida.
Key people
William E Horne
Chairman of the Board, Chief Executive Officer · since 2018
Patrick Kullmann
President · since 2018
Jeremy Daniel
Chief Financial Officer · since 2019
Ann Miller
Chief Operating Officer · since 2019
Dennis Moon
Senior Vice President · since 2013
James R. Andrews
Director · since 2013
Randal R. Betz
Director · since 2013
Jarrett Gorlin
Director · since 2018
Ron Lawson
Director · since 2016
Director · since 2016
Raymond Monteleone
Director · since 2019
Andre Terzic
Director · since 2019
Michael Yurkowsky
Director · since 2019
Scott M W Haufe
Independent Director · since 2013
Clyde A. Hennies
Independent Director · since 2013
Independent Director · since 2013
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||